Affimed

August 1st is #WorldLungCancerDay – started in 2012 as an effort to raise awareness of lung cancer, one of the most common and deadly cancers across the world, and to educate people about its risks, prevention, and symptoms in order to help increase early detection. At Affimed, we are developing novel therapies for hard-to-treat cancers including advanced non-small cell lung cancer (NSCLC) where patients too often have limited options. We are united in our shared vision of leveraging the innate immune system to create a future where cancer no longer derails the lives of patients and their loved ones. #AFM24 #InnateImmunity #ImmunoOncology #WhyWeFightCancer

We are #AffimedProud of all of our colleagues who joined more than 5,000 runners worldwide in the 13th National Center for Tumor Diseases (NCT) Heidelberg Virtual Run this July to help raise money for #CancerResearch. #nctrun #nctlauf #WhyWeFightCancer #TeamAffimed

Yesterday, Affimed reported first quarter 2024 financial results and provided a business update including new data from ongoing clinical trials with our ICE® acimtamig (AFM13) and AFM28. Read the full press release here: https://bit.ly/3Xkz820 #WhyWeFightCancer #AFMD #innateimmunity

Participating in #EHA2024?  Stop by our poster presentation featuring pre-clinical data on our ICE® #AFM28 from Affimed in collaboration with the group of Dr. Medyouf of the Institute for Tumor Biology and Experimental Therapy (Georg-Speyer-Haus Frankfurt). The poster shows that AFM28 can demonstrate significant anti-leukemic activity in both in vivo and ex vivo settings, including depletion of LSC-like cells. The poster presentation by Ioanna Tsoukala (Georg-Speyer-Haus) will take place on Friday, June 14, 2024, from 12:00 – 1:00 p.m. EDT. We look forward to seeing you there! #AFMD #AFM28 #InnateImmunity #WhyWeFightCancer #EHA2024

Reminder, as announced last week, our first quarter 2024 earnings call and corporate update will take place on Wednesday, June 12, 2024, at 8:30 a.m. EDT / 14:30 CET. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://bit.ly/43ACvls    #AFMD #InnateImmunity #WhyWeFightCancer

June is Cancer Immunotherapy Awareness Month. At Affimed we are focused on leveraging the immense power of the innate immune system to fight cancer by targeting and activating NK cells and macrophages with our ICE®. We are committed to developing novel therapies for hard-to-treat blood cancers and solid tumors where patients often have limited options. In this image, Christine Arnold and Andreas Premstaller, colleagues who bring their expertise to our on-going effort to leverage the innate immune system to fight cancer, share their perspective on #WhyWeFightCancer at Affimed. Find out more about our approach at www.affimed.com #InnateImmunity #ImmunoOncology #AFMD #Immunotherapy #CancerImmunotherapyAwarenessMonth

Affimed provides an update from the phase 2 study of AFM24 combined with atezolizumab (AFM24-102) in refractory NSCLC. Read the full press release here: https://bit.ly/4dQn0eT Listen to the webcast tonight, June 1, at 6:00 PM CDT: https://bit.ly/43ACvls

Reminder that Affimed is hosting a conference call / webcast for the financial community this evening. Link to Webcast: https://bit.ly/43ACvls #AFMD #AFM24 #ImmunoOncology #InnateImmunity #WhyWeFightCancer

Heading to #ASCO2024? Be sure to check out the poster presentations on our innate cell engager (ICE®) #AFM24 in combination with atezolizumab in in patients with EGFR-wildtype NSCLC.   The poster presentation by Hye Ryun Kim, Professor at Yonsei University College of Medicine, Seoul, Korea, will take place on Saturday, June 1, 2024, from 9:00 a.m. – 12:00 p.m. CDT.   We look forward to seeing you there! #AFMD #AFM24 #InnateImmunity #WhyWeFightCancer

Yesterday Affimed announced an update of the EGFR wild-type NSCLC cohort in the phase 2 AFM24-102 study of their ICE® AFM24 in combination with the check point inhibitor atezolizumab to be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.  The full data set will be presented at ASCO by Dr. Hye Ryun Kim, Professor at Yonsei University College of Medicine, Seoul, Korea, on June 1 during a poster session (9:00 a.m. - 12:00 p.m. CDT). Affimed will host a conference call / webcast on June 1, 2024, at 6:00 p.m. CDT / 7:00 p.m. EDT to discuss these results and to present initial clinical efficacy data from the non-small cell lung cancer EGFR mutant cohort of the study. Read the full press release here: https://bit.ly/4dN4jcd